** Shares of gene therapy developer Rocket Pharmaceuticals RCKT.O fall 3.9% to $12.98 premarket
** RCKT sold 13.2 mln shares in an upsized public offering at $12.50/shr for gross proceeds of $165 mln
** Offering size was boosted from the $150 mln worth of shares announced on Tuesday, priced at a 7.5% discount to stock's last close of $13.51
** Additionally, on Tuesday, life sciences investment firm RTW had agreed to purchase pre-funded warrants representing the right to purchase $5 mln worth of RCKT shares in a concurrent private placement
** Morgan Stanley, Leerink Partners and Cantor were the joint book-running managers for the offering
** RCKT had 91.2 mln outstanding shares as of Sept. 30, according to an SEC filing, giving it a $1.23 bln market capitalization as of most recent closing price
** As of last close, RCKT shares down 54.9% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。